Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future Document date: 2017_3_28
ID: 0fegsm1v_108
Snippet: Similarly, new opportunities have been created by the development of antibody-drug conjugates (ADCs) to treat the infectious diseases or target cancer cells. ADCs are being developed by progressing in antibody generation, selection of exceedingly cytotoxic molecules, and construction of stable linkers that can be investigated in clinical trials (Vincent and Zurini, 2012) . Cytotoxic therapeutic mAbs often help target cell-killing by eliciting imm.....
Document: Similarly, new opportunities have been created by the development of antibody-drug conjugates (ADCs) to treat the infectious diseases or target cancer cells. ADCs are being developed by progressing in antibody generation, selection of exceedingly cytotoxic molecules, and construction of stable linkers that can be investigated in clinical trials (Vincent and Zurini, 2012) . Cytotoxic therapeutic mAbs often help target cell-killing by eliciting immune effector functions. These include antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) mediated by innate immune effector cells, and complementdependent cytotoxicity (CDC) mediated by humoral components (Figure 6) . in vitro studies, Fc engineering methods have been specifically designed to modulate ADCC, ADCP, and CDC envisioned for therapeutic mediation (Kinder et al., 2015) .
Search related documents:
Co phrase search for related documents- cell killing and effector cell: 1, 2, 3, 4, 5
- cell killing and new opportunity: 1
- cell killing and vitro study: 1, 2, 3
- cell killing target and effector cell: 1
- cell mediate and clinical trial: 1
- cell mediate and effector cell: 1, 2, 3, 4, 5, 6, 7
- cell mediate and effector function: 1
- cell mediate and immune effector cell: 1
- cell mediate and infectious disease: 1, 2
- cellular phagocytosis and clinical trial: 1, 2, 3
- cellular phagocytosis and complementdependent cytotoxicity: 1
- cellular phagocytosis and effector cell: 1, 2, 3
- cellular phagocytosis and effector function: 1
- clinical trial and effector cell: 1, 2, 3
- clinical trial and effector function: 1, 2
- clinical trial and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- clinical trial and infectious disease treat: 1, 2
- clinical trial and new opportunity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical trial and vitro study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date